Review ArticleReview

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints

Niki Karachaliou, Maria Gonzalez Cao, Cristina Teixidó, Santiago Viteri, Daniela Morales-Espinosa, Mariacarmela Santarpia and Rafael Rosell
Cancer Biology & Medicine June 2015, 12 (2) 79-86; DOI: https://doi.org/10.7497/j.issn.2095-3941.2015.0029

References

  1. 1.↵
    2. Siegel R,
    3. Ma J,
    4. Zou Z,
    5. Jemal A.
    Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Rosell R,
    3. Bivona TG,
    4. Karachaliou N.
    Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013;382:720–731.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.
    2. Rosell R,
    3. Karachaliou N,
    4. Wolf J,
    5. Ou SH.
    ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med 2014;2:966–968.
    OpenUrl
  4. 4.↵
    2. Rosell R.
    Dynamic Evolution of ALK Positive Non-Small Cell Lung Cancers and Management of Associated Brain Metastases [podcast]. J Clin Oncol 2015. [Epub ahead of print].
  5. 5.↵
    2. Kilinc MO,
    3. Gu T,
    4. Harden JL,
    5. Virtuoso LP,
    6. Egilmez NK.
    Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol 2009;182:4217–4225.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Zamarron BF,
    3. Chen W.
    Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7:651–658.
    OpenUrlPubMed
  7. 7.↵
    2. Luckheeram RV,
    3. Zhou R,
    4. Verma AD,
    5. Xia B.
    CD4T cells: differentiation and functions. Clin Dev Immunol 2012;2012:925135.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Zou W.
    Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–274.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Kryczek I,
    3. Wei S,
    4. Gong W,
    5. Shu X,
    6. Szeliga W,
    7. Vatan L, et al.
    Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol 2008;181:5842–5846.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Gershon RK,
    3. Kondo K.
    Infectious immunological tolerance. Immunology 1971;21:903–914.
    OpenUrlPubMedWeb of Science
  11. 11.
    2. Gershon RK,
    3. Kondo K.
    Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723–737.
    OpenUrlPubMedWeb of Science
  12. 12.
    2. Berendt MJ,
    3. North RJ.
    T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980;151:69–80.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    2. Bursuker I,
    3. North RJ.
    Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984;159:1312–1321.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. North RJ,
    3. Bursuker I.
    Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 1984;159:1295–1311.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Sakaguchi S,
    3. Sakaguchi N,
    4. Asano M,
    5. Itoh M,
    6. Toda M.
    Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–1164.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Hori S,
    3. Nomura T,
    4. Sakaguchi S.
    Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Heikkinen T,
    3. Järvinen A.
    The common cold. Lancet 2003;361:51–59.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    2. Greenwald RJ,
    3. Freeman GJ,
    4. Sharpe AH.
    The B7 family revisited. Annu Rev Immunol 2005;23:515–548.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Townsend SE,
    3. Allison JP.
    Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368–370.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Riley JL,
    3. June CH.
    The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005;105:13–21.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Nirschl CJ,
    3. Drake CG.
    Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19:4917–4924.
    OpenUrlAbstract/FREE Full Text
  22. 22.
    2. Ngiow SF,
    3. von Scheidt B,
    4. Akiba H,
    5. Yagita H,
    6. Teng MW,
    7. Smyth MJ.
    Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540–3551.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Wang L,
    3. Rubinstein R,
    4. Lines JL,
    5. Wasiuk A,
    6. Ahonen C,
    7. Guo Y, et al.
    VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011;208:577–592.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Chemnitz JM,
    3. Parry RV,
    4. Nichols KE,
    5. June CH,
    6. Riley JL.
    SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945–954.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Yokosuka T,
    3. Takamatsu M,
    4. Kobayashi-Imanishi W,
    5. Hashimoto-Tane A,
    6. Azuma M,
    7. Saito T.
    Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201–1217.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Su JC,
    3. Chiang HC,
    4. Tseng PH,
    5. Tai WT,
    6. Hsu CY,
    7. Li YS, et al.
    RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis 2014;35:2807–2814.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Tang TL,
    3. Freeman RM Jr.,
    4. O’Reilly AM,
    5. Neel BG,
    6. Sokol SY.
    The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 1995;80:473–483.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.
    2. Bennett AM,
    3. Hausdorff SF,
    4. O’Reilly AM,
    5. Freeman RM,
    6. Neel BG.
    Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell Biol 1996;16:1189–1202.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Lehmann U,
    3. Schmitz J,
    4. Weissenbach M,
    5. Sobota RM,
    6. Hortner M,
    7. Friederichs K, et al.
    SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003;278:661–671.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Hodi FS,
    3. O’Day SJ,
    4. McDermott DF,
    5. Weber RW,
    6. Sosman JA,
    7. Haanen JB, et al.
    Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Sharma P,
    3. Allison JP.
    The future of immune checkpoint therapy. Science. 2015;348:56–61.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Freedman LR,
    3. Cerottini JC,
    4. Brunner KT.
    In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 1972;109:1371–1378.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Fridman WH,
    3. Pagès F,
    4. Sautès-Fridman C,
    5. Galon J.
    The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298–306.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    2. Dunn GP,
    3. Old LJ,
    4. Schreiber RD.
    The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329–360.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Ahmadzadeh M,
    3. Johnson LA,
    4. Heemskerk B,
    5. Wunderlich JR,
    6. Dudley ME,
    7. White DE, et al.
    Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–1544.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Wang QJ,
    3. Hanada K,
    4. Robbins PF,
    5. Li YF,
    6. Yang JC.
    Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012;72:6119–6129.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. Dong H,
    3. Strome SE,
    4. Salomao DR,
    5. Tamura H,
    6. Hirano F,
    7. Flies DB, et al.
    Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    2. Parsa AT,
    3. Waldron JS,
    4. Panner A,
    5. Crane CA,
    6. Parney IF,
    7. Barry JJ, et al.
    Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84–88.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    2. Marzec M,
    3. Zhang Q,
    4. Goradia A,
    5. Raghunath PN,
    6. Liu X,
    7. Paessler M, et al.
    Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008;105:20852–20857.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    2. Liu J,
    3. Hamrouni A,
    4. Wolowiec D,
    5. Coiteux V,
    6. Kuliczkowski K,
    7. Hetuin D, et al.
    Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296–304.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Taube JM,
    3. Anders RA,
    4. Young GD,
    5. Xu H,
    6. Sharma R,
    7. McMiller TL, et al.
    Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    2. Ghebeh H,
    3. Tulbah A,
    4. Mohammed S,
    5. Elkum N,
    6. Bin Amer SM,
    7. Al-Tweigeri T, et al.
    Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121:751–758.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    2. Zhu J,
    3. Chen L,
    4. Zou L,
    5. Yang P,
    6. Wu R,
    7. Mao Y, et al.
    MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014;75:348–353.
    OpenUrlCrossRefPubMed
  44. 44.↵
    2. Yamamoto R,
    3. Nishikori M,
    4. Tashima M,
    5. Sakai T,
    6. Ichinohe T,
    7. Takaori-Kondo A, et al.
    B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009;100:2093–2100.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Hirahara K,
    3. Ghoreschi K,
    4. Yang XP,
    5. Takahashi H,
    6. Laurence A,
    7. Vahedi G, et al.
    Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012;36:1017–1030.
    OpenUrlCrossRefPubMed
  46. 46.
    2. Konishi J,
    3. Yamazaki K,
    4. Azuma M,
    5. Kinoshita I,
    6. Dosaka-Akita H,
    7. Nishimura M.
    B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094–5100.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    2. Mu CY,
    3. Huang JA,
    4. Chen Y,
    5. Chen C,
    6. Zhang XG.
    High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682–688.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Wölfle SJ,
    3. Strebovsky J,
    4. Bartz H,
    5. Sähr A,
    6. Arnold C,
    7. Kaiser C, et al.
    PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011;41:413–424.
    OpenUrlCrossRefPubMed
  49. 49.↵
    2. Pivarcsi A,
    3. Müller A,
    4. Hippe A,
    5. Rieker J,
    6. van Lierop A,
    7. Steinhoff M, et al.
    Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007;104:19055–19060.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    2. Xu C,
    3. Fillmore CM,
    4. Koyama S,
    5. Wu H,
    6. Zhao Y,
    7. Chen Z, et al.
    Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014;25:590–604.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    2. Akbay EA,
    3. Koyama S,
    4. Carretero J,
    5. Altabef A,
    6. Tchaicha JH,
    7. Christensen CL, et al.
    Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355–1363.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    2. D’Incecco A,
    3. Andreozzi M,
    4. Ludovini V,
    5. Rossi E,
    6. Capodanno A,
    7. Landi L, et al.
    PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95–102.
    OpenUrlCrossRefPubMed
  53. 53.↵
    2. Azuma K,
    3. Ota K,
    4. Kawahara A,
    5. Hattori S,
    6. Iwama E,
    7. Harada T, et al.
    Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014;25:1935–1940.
    OpenUrlCrossRefPubMed
  54. 54.↵
    2. Zhang Y,
    3. Wang L,
    4. Li Y,
    5. Pan Y,
    6. Wang R,
    7. Hu H, et al.
    Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567–573.
    OpenUrlPubMed
  55. 55.↵
    2. Gainor JF,
    3. Sequist LV,
    4. Shaw AT,
    5. Azzoli CG,
    6. Piotrowska Z,
    7. Huynh T, et al.
    Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr 8012.
  56. 56.↵
    2. Robert C,
    3. Thomas L,
    4. Bondarenko I,
    5. O’Day S,
    6. Weber J,
    7. Garbe C, et al.
    Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    2. Schadendorf D,
    3. Hodi FS,
    4. Robert C,
    5. Weber JS,
    6. Margolin K,
    7. Hamid O, et al.
    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015;33:1889–1894.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    2. Hamid O,
    3. Robert C,
    4. Daud A,
    5. Hodi FS,
    6. Hwu WJ,
    7. Kefford R, et al.
    Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–144.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    2. Robert C,
    3. Long GV,
    4. Brady B,
    5. Dutriaux C,
    6. Maio M,
    7. Mortier L, et al.
    Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–330.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    2. Paz-Ares L,
    3. Horn L,
    4. Borghaei H,
    5. Spigel DR,
    6. Steins M,
    7. Ready N, et al.
    Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr LBA109.
  61. 61.↵
    2. Brahmer J,
    3. Reckamp KL,
    4. Baas P,
    5. Crinò L,
    6. Eberhardt WE,
    7. Poddubskaya E, et al.
    Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015. [Epub ahead of print].
  62. 62.↵
    2. Tumeh PC,
    3. Harview CL,
    4. Yearley JH,
    5. Shintaku IP,
    6. Taylor EJ,
    7. Robert L, et al.
    PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–571.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    2. Herbst RS,
    3. Soria JC,
    4. Kowanetz M,
    5. Fine GD,
    6. Hamid O,
    7. Gordon MS, et al.
    Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–567.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    2. Topalian SL,
    3. Hodi FS,
    4. Brahmer JR,
    5. Gettinger SN,
    6. Smith DC,
    7. McDermott DF, et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    2. Alexandrov LB,
    3. Nik-Zainal S,
    4. Wedge DC,
    5. Aparicio SA,
    6. Behjati S,
    7. Biankin AV, et al.
    Signatures of mutational processes in human cancer. Nature 2013;500:415–421.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    2. Rizvi NA,
    3. Hellmann MD,
    4. Snyder A,
    5. Kvistborg P,
    6. Makarov V,
    7. Havel JJ, et al.
    Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–128.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    2. Snyder A,
    3. Makarov V,
    4. Merghoub T,
    5. Yuan J,
    6. Zaretsky JM,
    7. Desrichard A, et al.
    Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–2199.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    2. Schumacher TN,
    3. Schreiber RD.
    Neoantigens in cancer immunotherapy. Science 2015;348:69–74.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    2. Schumacher TN,
    3. Kesmir C,
    4. van Buuren MM.
    Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12–14.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords